Sunday, November 06, 2016 2:53:48 PM
By Bryant Furlow October 27, 2016
From the Onco Therapy Network (first time I read something related to Bavi)
http://www.oncotherapynetwork.com/breast-cancer-targets/anti-ps-antibodies-enhances-pd-l1-immune-checkpoint-blockade-triple-negative-breast-cancer (my apologies if this has already been posted)
Peregrine Pharmaceuticals has announced preliminary findings from preclinical research showing that antiphosphatidylserine (PS) antibodies “similar to bavituximab” improves anti-PD-L1 immune checkpoint blockade’s antitumor activity in a mouse model of triple-negative breast cancer (TNBC).
Duke University Medical Center researchers presented (Poster Session B36) the findings at the American Association for Cancer Research (AACR)’s Tumor Immunology and Immunotherapy Conference, held October 20-23, 2016, in Boston.
The research team found that PS enhanced anti-PD-L1 therapy’s antitumor activity in the E0771 mouse model of TNBC after chemotherapy, radiotherapy, or photodynamic therapy.
Chemotherapy, radiotherapy, and photodynamic therapy were all associated with subsequently increased PS expression on tumor cells, the researchers noted.
“PS expression is upregulated by chemotherapy, radiotherapy, and photodynamic therapy in vitro,” reported lead study author Kensuke Kaneko, PhD, of Duke University in Durham, NC, and coauthors in the poster session. “A combination therapy blocking PS by PS-targeting mAb and immune checkpoint blockade with anti-PD-L1 mAb appears superior to single-agent therapy.”
Combining anti-PS and anti-PD-L1 therapy, with or without paclitaxel chemotherapy, “led to greater antitumor responses than any of the treatments administered as single agents or duel treatment combinations with paclitaxel,” the company announced.
The study is the latest in a series of such small, proof-of-concept preliminary studies. The company’s preclinical research employs ch1N11, “the preclinical equivalent of bavituximab,” in its animal studies.
Bavituximab (and mch1N11 [a novel mouse chimeric monoclonal antibody that targets PS]), investigational monoclonal antibodies, targets PS and PS-mediated inhibition of immune cell recognition of tumor cells; it is believed to weaken tumor-environment immunosuppression and thereby enhance tumor infiltration by lymphocytes. It also appears to decrease expression of tumor-promoting cytokines, which are elevated following anti-PD-1 monotherapy.
“Our future plan is to investigate the effect of local irradiation or photodynamic therapy combined with PS-targeting mAb and anti-PD-L1 Ab,” the coauthors reported.
Preliminary preclinical work has also shown that PS is associated with enhanced PD-1 and CTLA-4 blockade antitumor activity in mouse models of melanoma.
The National Comprehensive Cancer Network (NCCN) has recently announced grants for clinical study of bavituximab combination immunotherapy regimens against glioblastoma, head and neck cancer, and liver carcinoma, Peregrine announced.
Recent CDMO News
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM